Form 4: OptimizeRx Corp Executive Reports Stock Transactions
SEC Form 4 Filing
Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the vesting and conversion of restricted stock units into common stock, along with a disposition of shares to cover tax obligations.
Summary
- On March 1, 2024, Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, had 771 restricted stock units vest and convert into 771 shares of common stock.
- Also on March 1, 2024, 268 shares of common stock were disposed of at a price of $15.95 to satisfy tax withholding obligations.
- Following these transactions, Odence-Ford directly owns 14,231 shares of OptimizeRx Corp common stock.
- The restricted stock units vest in three equal annual installments beginning March 1, 2023.
Sentiment
Score: 5
Explanation: This is a neutral filing reflecting standard executive compensation practices and tax obligations.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve a small number of shares relative to the total outstanding.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | First vesting date of restricted stock units. |
| 03/01/2024 | Restricted stock units vested and converted to common stock; shares disposed of for tax obligations. |
| 03/06/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.